ANI Pharmaceuticals, Alimera Sciences
Alimera Sciences falls after it sues ANI Pharmaceuticals to close deal (update)
Alimera Sciences (NASDAQ:ALIM) plummeted 25% in premarket trading after it said it filed a lawsuit against ANI Pharmaceuticals (ANIP) to compel the company to close its acquisition of Alimera. Alimera’s (ALIM) lawsuit asks the court to require ANI to comply with its obligations to complete the transaction as contemplated by the merger agreement,
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer,
ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced
ANI Pharmaceuticals completes purchase of Alimera Sciences
ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of the merger agreement, ANI acquired all of the outstanding shares of Alimera for $5.
ANI Pharmaceuticals completes acquisition of Alimera Sciences
The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds
Alimera Sciences: Deal Closing After All, CVR Still Attractive
ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an attractive opportunity. Read more on ALIM.
Alimera Files Lawsuit Against ANI To Enforce Merger Deal, Stock Down Nearly 19%
Alimera Sciences, Inc. (ALIM), a biopharmaceutical company, announced on Tuesday that it has filed a lawsuit in the Delaware Court of ...
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest ...
Alimera Sciences Shares Slide on Merger Lawsuit
On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...
bovnews8d
What’s Causing Alimera Sciences Inc (ALIM) Stock’s 44.39% Jump Over the Last Six Months?
Alimera Sciences Inc (ALIM) stock saw a modest uptick, ending the day at $5.53 which represents a slight increase of $0.34 or 6.55% from the prior close of $5.19. The stock opened at $5.53 and touched ...
Future Market Insights15h
Global Diabetic Macular Edema Market Set for Steady Expansion, Projected to Reach USD 4,642.9 Million by 2034
Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.